Co-administration of treatment for rifampicin-resistant TB and chronic HCV infection: A TBnet and ESGMYC study

ObjectivesLimited evidence is available on the co-administration of treatment for hepatitis C virus (HCV) and multidrug-resistant tuberculosis (MDR-TB). The objective of this study is to assess safety and effectiveness of concomitant treatment of chronic HCV-infection and MDR-TB.MethodsWe performed...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	The Journal of infection Ročník 84; číslo 6; s. 834 - 872
Hlavní autoři:	Tunesi, Simone, Dû, Damien Le, Gualano, Gina, Millet, Joan-Pau, Skrahin, Aliaksandr, Bothamley, Graham, Casas, Xavier, Goletti, Delia, Lange, Christoph, Musso, Maria, Palmieri, Fabrizio, Pourcher, Valérie, Rioux, Christophe, Skrahina, Alena, Veziris, Nicolas, Viatushka, Dzmitry, Jachym-Fréchet, Mathilde, Guglielmetti, Lorenzo, Marigot-Outtandy, Dhiba, Lescure, Xavier, Dubert, Marie, Yazdanpanah, Yazdan, Caumes, Eric, Choinier, Pascaline, Haddad, Elie, Kowalczyk, Jakub, Laurichesse, Hélène, Lesens, Olivier, Aubry, Alexandra, Bonnet, Isabelle, Morel, Florence
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Elsevier Ltd 01.06.2022 Elsevier
Témata:	Antitubercular Agents - therapeutic use Hepatitis C - drug therapy Human health and pathology Humans Infectious diseases Life Sciences Pulmonology and respiratory tract Rifampin - therapeutic use Tuberculosis, Multidrug-Resistant - drug therapy MDR antiviral tuberculosis
ISSN:	0163-4453, 1532-2742, 1532-2742
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Popis
Shrnutí:	ObjectivesLimited evidence is available on the co-administration of treatment for hepatitis C virus (HCV) and multidrug-resistant tuberculosis (MDR-TB). The objective of this study is to assess safety and effectiveness of concomitant treatment of chronic HCV-infection and MDR-TB.MethodsWe performed a retrospective, multicentre observational cohort study of patients treated concomitantly for multidrug-resistant tuberculosis and HCV-infection between January 2015 and February 2021.ResultsOverall, 23 patients were enrolled across six centres in four countries. Predominant HCV genotype was 3 (40%) and most patients had absent or mild liver fibrosis. All patients completed HCV treatment without interruptions and achieved undetectable plasmatic HCV-RNA from week 12. Sustained virological response was equally obtained for all patients with available results. Among 11 patients who had finished MDR-TB treatment at data censoring, 10 achieved cure and one died. Overall, 18 liver-related adverse events were reported in 48% of patients, the majority (94%) occurring during MDR-TB treatment but before HCV treatment was started. No liver-related serious adverse events or Grade 4 adverse events were reported.ConclusionsConcomitant treatment of HCV and MDR-TB was well tolerated and effective. HCV treatment should be considered in MDR-TB patients to reduce treatment-related hepatotoxicity and prevent progression of HCV-mediated liver disease.
Bibliografie:	content type line 23 SourceType-Scholarly Journals-1 ObjectType-Correspondence-1
ISSN:	0163-4453 1532-2742 1532-2742
DOI:	10.1016/j.jinf.2022.03.004